NL301118I1 - - Google Patents

Info

Publication number
NL301118I1
NL301118I1 NL301118C NL301118C NL301118I1 NL 301118 I1 NL301118 I1 NL 301118I1 NL 301118 C NL301118 C NL 301118C NL 301118 C NL301118 C NL 301118C NL 301118 I1 NL301118 I1 NL 301118I1
Authority
NL
Netherlands
Prior art keywords
methyl
dioxoethyl
phosphonooxy
hpmc
pyrrolo
Prior art date
Application number
NL301118C
Other languages
English (en)
Dutch (nl)
Other versions
NL301118I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NL301118I1 publication Critical patent/NL301118I1/nl
Application filed filed Critical
Publication of NL301118I2 publication Critical patent/NL301118I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL301118C 2008-09-04 2021-07-26 Fostemsavir NL301118I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
PCT/US2009/055820 WO2010028108A2 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (2)

Publication Number Publication Date
NL301118I1 true NL301118I1 (enExample) 2021-07-23
NL301118I2 NL301118I2 (nl) 2022-02-22

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301118C NL301118I2 (nl) 2008-09-04 2021-07-26 Fostemsavir

Country Status (16)

Country Link
US (2) US20100056540A1 (enExample)
EP (1) EP2323633B1 (enExample)
JP (1) JP5638527B2 (enExample)
CN (1) CN102143739B (enExample)
AT (1) ATE550016T1 (enExample)
CA (1) CA2735008C (enExample)
CY (1) CY1112816T1 (enExample)
DK (1) DK2323633T3 (enExample)
ES (1) ES2383149T3 (enExample)
HR (1) HRP20120441T1 (enExample)
NL (1) NL301118I2 (enExample)
PL (1) PL2323633T3 (enExample)
PT (1) PT2323633E (enExample)
SI (1) SI2323633T1 (enExample)
SM (1) SMT201200029B (enExample)
WO (1) WO2010028108A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
CA2735008C (en) 2016-11-29
SMT201200029B (it) 2012-09-07
CN102143739B (zh) 2014-12-17
WO2010028108A3 (en) 2010-09-02
US20150158891A1 (en) 2015-06-11
JP2012502042A (ja) 2012-01-26
CY1112816T1 (el) 2016-02-10
PT2323633E (pt) 2012-05-29
ES2383149T3 (es) 2012-06-18
HRP20120441T1 (hr) 2012-06-30
EP2323633B1 (en) 2012-03-21
CA2735008A1 (en) 2010-03-11
US20100056540A1 (en) 2010-03-04
CN102143739A (zh) 2011-08-03
PL2323633T3 (pl) 2012-08-31
DK2323633T3 (da) 2012-07-09
WO2010028108A2 (en) 2010-03-11
ATE550016T1 (de) 2012-04-15
EP2323633A2 (en) 2011-05-25
NL301118I2 (nl) 2022-02-22
JP5638527B2 (ja) 2014-12-10
SI2323633T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
GB2459393B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
ZA200805063B (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
MX2011013400A (es) Novedoso derivado de fenilimidazol como inhibidores de la enzima pde10a.
WO2008015517A3 (en) Ep2 agonists
MX2011006578A (es) Formulaciones farmaceuticas de liberacion prolongada.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
EP3492069A3 (en) Pharmaceutical compositions
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
TW200716105A (en) Imidazole compounds
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
TNSN08369A1 (en) Benzimidazole derivatives
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NL301118I1 (enExample)
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
UA94953C2 (en) Ep2 agonists
WO2009007747A3 (en) Hydantoin derivatives used as mmp12 inhibitors
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
SG158015A1 (en) New azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them
HK1137147B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008129004A3 (en) Heterocyclic compounds containing the morpholine nucleus their preparation and use
TW200833325A (en) Pharmaceutical composition comprising ascorbic acid
TN2011000612A1 (en) Novel phenylimidazole derivative as pde 10a enzyme inhibitor
UA93689C2 (ru) Фармацевтическая композиция ингибиторов дипептидилпептидазы